Références

1. Gheit T. Mucosal and Cutaneous Human Papillomavirus Infections and Cancer Biology. Front Oncol. 2019 May 8;9:355. doi: 10.3389/fonc.2019.00355. PMID: 31134154; PMCID: PMC6517478.

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.

3. Brou EC, Okou DT, Kiki-Barro PC. Prévalence et distribution des virus du papillome humain chez les femmes en Côte d´Ivoire: revue systématique. PAMJ-One Health. 2025 Oct 24;18(12). doi:10.11604/pamj-oh.2025.18.12.46914

4. OMS | Bureau régional pour l'Afrique. Plaidoyer pour la prévention et la lutte contre le cancer du col de l'utérus en Afrique [Internet]. 2026 [cited 2026 May 20]. Available from: https://www.afro.who.int/fr/publications/plaidoyer-pour-la-prevention-et-la-lutte-contre-le-cancer-du-col-de-luterus-en-0

5. IARC Working Group on the Evaluation of Cancer-Preventive Interventions. Cervical Cancer Screening. Lyon (FR): International Agency for Research on Cancer; 2022. (IARC Handbooks of Cancer Prevention, No. 18.) 2., Cervical Cancer Screening Programmes.

6. Endale HT, Negash HK, Getnet M, Asefa T, Gela YY, Tesfaye W, et al. Cervical cancer screening uptake in East Africa: a systematic review and meta-analysis of observational studies. BMC Public Health. 2025 Aug 19;25:2831. doi:10.1186/s12889-025-24094-0 PubMed PMID: 40830782; PubMed Central PMCID: PMC12363099.

7. Zhou X, Xu H, Fu Y, Nie Q, Zhang B, Guo X, et al. Geographic and demographic patterns of cervical cancer in Africa using GLOBOCAN 2022. BMC Cancer. 2026 Apr 18. doi:10.1186/s12885-026-16000-7

8. OMS | Bureau régional pour l'Afrique. Cervical cancer [Internet]. 2026 [cited 2026 May 20]. Available from: https://www.afro.who.int/health-topics/cervical-cancer

9. Burayu ET, Degefa BD, Zegeye ZB, Bekele GG. Incidence and predictors of mortality among cervical cancer patients in Sub-Saharan Africa: a systematic review and meta-analysis. AJOG Global Reports. 2025 Nov 1;5(4):100570. doi:10.1016/j.xagr.2025.100570

10. National Institutes of Health. HIV and Human Papillomavirus [Internet]. [cited 2026 May 20]. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-human-papillomavirus

11. Broshkevitch CJ, Barnabas RV, Liu G, Palanee-Phillips T, Rao DW. Enhanced cervical cancer and HIV interventions reduce the disproportionate burden of cervical cancer cases among women living with HIV: A modeling analysis. PLoS One. 2024 May 23;19(5):e0301997. doi: 10.1371/journal.pone.0301997. PMID: 38781268; PMCID: PMC11115290.

12. Ajah, M.I., Dibua, M.E.U., Ajah, L.O. *et al*. Exploring the role of cervicovaginal microbiota as risk factor for cervical cancer in Sub-Saharan Africa: a systematic review and meta-analysis. *BMC Women's Health* 25, 160 (2025). https://doi.org/10.1186/s12905-025-03688-1

13. Berihun Agegn Mengistie, Getie Mihret Aragaw, Tazeb Alemu Anteneh, Kindu Yinges Wondie,Alemneh Tadesse Kassie, Alemken Eyayu Abuhay, Wondimnew Mersha Biset, Gebrye Gizaw Mulatu, Nuhamin Tesfa Tsega. Prevalence and determinants of precancerous cervical lesions among women screened for cervical cancer in Africa: A systematic review and meta-analysis | PLOS One [Internet]. [cited 2026 May 20]. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0338484

14. OMS | Bureau régional pour l'Afrique. Un vaccin à dose unique contre le VPH pour faire progresser les efforts de vaccination [Internet]. 2026 [cited 2026 May 20]. Available from: https://www.afro.who.int/fr/news/un-vaccin-dose-unique-contre-le-vph-pour-faire-progresser-les-efforts-de-vaccination

15. Bolarinwa O, Bashir SG, Okyere J, et al. Burden, Regional Trends and Risk Factors of Breast, Cervical, Uterine, and Ovarian Cancers in Sub-Saharan Africa, 1990-2023: The Global Burden of Disease 2023. Int J Environ Res Public Health. 2026;23(4):419.

16. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020 Feb;8(2):e180-e190. doi: 10.1016/S2214-109X(19)30488-7. Epub 2019 Dec 17. PMID: 31862245.

17. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010 Dec 15;202(12):1789-99. doi: 10.1086/657321. Epub 2010 Nov 10. PMID: 21067372.

18. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002 May;2(5):342-50. doi: 10.1038/nrc798. PMID: 12044010.

19. Harper DM, DeMars LR. HPV vaccines - A review of the first decade. Gynecol Oncol.

2017 Jul;146(1):196-204. doi: 10.1016/j.ygyno.2017.04.004. Epub 2017 Apr 22. Erratum in: Gynecol Oncol. 2017 Nov;147(2):489. doi: 10.1016/j.ygyno.2017.08.019. PMID: 28442134.

20. zur Hausen H. (1976). Condylomata acuminata and human genital cancer. *Cancer Res*, 36(2):794.

21. Dürst M, Gissmann L, Ikenberg H, zur Hausen H. (1983). A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. *Proc Natl Acad Sci USA*, 80(12):3812-3815.

22. Boshart M, Gissmann L, Ikenberg H, et al. (1984). A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. *EMBO J*, 3(5):1151-1157.

23. Zhou J, Sun XY, Stenzel DJ, Frazer IH. (1991). Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. *Virology*, 185(1):251-257.

24. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G; GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004 Nov 13-19;364(9447):1757-65. doi: 10.1016/S0140-6736(04)17398-4. PMID: 15541448.

25. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 May 10;356(19):1915-27. doi: 10.1056/NEJMoa061741. PMID: 17494925.

26. McLemore MR. Gardasil: Introducing the new human papillomavirus vaccine. Clin J Oncol Nurs. 2006 Oct;10(5):559-60. doi: 10.1188/06.CJON.559-560. PMID: 17063609.

27. European Medicines Agency (EMA). Cervarix [Internet]. 2018 [cited 2026 May 24]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cervarix

28. Joura EA, Giuliano AR, Iversen OE, et al. (2015). A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. *N Engl J Med*, 372(8):711-723.

29. World Health Organization (WHO). (2022). *Human papillomavirus vaccines: WHO position paper, December 2022*. *Wkly Epidemiol Rec*, 97(50):645-672.

30. Kirnbauer R, Booy F, Cheng N, et al. (1992). Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. *Proc Natl Acad Sci USA*, 89(24):12180-12184.

31. Schiller JT, Lowy DR. (2018). HPV vaccines: a review of the first decade. *Gynecol Oncol*, 150(3):434-442.

32. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection

and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6. Erratum in: Lancet. 2010 Sep 25;376(9746):1054. PMID: 19586656.

33. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020 Feb;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6. Epub 2019 Dec 4. Erratum in: Lancet Glob Health. 2022 Jan;10(1):e41. doi: 10.1016/S2214-109X(21)00554-4. PMID: 31812369; PMCID: PMC7025157.

34. Giuliano AR, Palefsky JM, Goldstone S, et al. (2011). Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. *N Engl J Med*, 364(5):401-411.

35. World Health Organization (WHO). (2017). *Human papillomavirus vaccines: WHO position paper, May 2017*. *Wkly Epidemiol Rec*, 92(19):241-268.

36. Baird HD, Rothschild M, Ekanayake K, et al. (2022). Single-Dose HPV Vaccine Efficacy in Young Women (DoRIS Trial). *N Engl J Med*, 387(24):2211-2222.

37. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al. (2021). Efficacy and immunogenicity of a single dose of human papillomavirus vaccine. *Lancet Oncol*, 22(4):555-567.

38. Barnabas RV, Brown ER, Onchonga FA, et al. (2023). Single-dose HPV vaccine immunity and protection in Kenyan adolescent girls and young women (KEN SHE Study). *Lancet Glob Health*, 11(4):e521-e531.

39. Prem K, Jit M, Brisson M, et al. (2021). Cost-effectiveness of single-dose HPV vaccination in low- and middle-income countries. *Lancet Glob Health*, 9(12):e1674-e1684.

40. Watson-Jones D, Mchome B, Mchunu G, et al. (2022). Acceptability of single-dose HPV vaccination in Tanzania and Kenya. *Vaccine*, 40(32):4567-4575.

41. Cameroon NITAG (2022). Note de recommandation n° 009/2022 du Groupe Technique Consultatif National pour la

Vaccination, Sur les options de calendrier vaccinal anti HPV

42. Cheuyem FZL, Achangwa C, Tchamani R, Tsapi AT, Guissana EO, Ekoum EM, et al. Human papillomavirus vaccine acceptability in Cameroon: a systematic review and meta-analysis [Internet]. medRxiv; 2026 [cited 2026 May 24]. p. 2026.04.28.26351975. Available from: https://www.medrxiv.org/content/10.64898/2026.04.28.26351975v1 doi:10.64898/2026.04.28.26351975

43. Drolet M, Bénard É, Pérez N, Brisson M; HPV Vaccination Impact Study Group. (2019). Population-level impact and herd effects following the introduction of HPV vaccination programmes: updated systematic review and meta-analysis. *Lancet*, 394(10197):497-509.

44. Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JM, Saville M, Frazer IH, Canfell K. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019 Jan;4(1):e19-e27. doi: 10.1016/S2468-2667(18)30183-X. Epub 2018 Oct 2. PMID: 30291040.

45. Tabrizi SN, Brotherton JM, Kaldor JM, et al. (2019). Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. *Lancet Infect Dis*, 19(12):1371-1381.

46. Brotherton JM, Gertig DM, May C, et al. (2019). HPV vaccine impact in Australian women: a systematic review and meta-analysis. *Papillomavirus Res*, 7:86-93.

47. Chow EP, Machalek DA, Tabrizi SN, et al. (2017). Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female vaccine program. *Sex Transm Infect*, 93(3):204-209.

48. Falcaro M, Castañon A, Ndlela B, et al. (2021). The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. *Lancet*, 398(10316):2084-2092.

49. Mesenbrink P, Kops NL, Bessel M, et al. (2022). Impact of HPV vaccination on cervical cancer and precancerous lesions in Portugal. *Eur J Public Health*, 32(4):619-625.

50. Lei J, Ploner A, Elfström KM, et al. (2020). HPV vaccination and the risk of invasive cervical cancer. *N Engl J Med*, 383(14):1340-1348.

51. World Health Organization (WHO). (2020). *Global strategy to accelerate the elimination of cervical cancer as a public health problem*. Geneva: WHO.

52. Brisson M, Bénard É, Drolet M, et al. (2016). Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. *Lancet Public Health*, 1(1):e8-e17.

53. Njoh AA, Waheed DE, Kedakse TSNJ, Ebongue LJ, Kongnyuy EJ, Amani A, Tambasho AC, Saidu Y, Kaba MI, Sangwe CN, Kenfack H, Seungue J, Nebongo D, Nnang NE, Vorsters A, Cleenewerck de Kiev L. Overcoming challenges and achieving high HPV vaccination uptake in Cameroon: lessons learned from a gender-neutral and single-dose program and community engagement. BMC Public Health. 2025 May 8;25(1):1696. doi: 10.1186/s12889-025-22776-3. PMID: 40340822; PMCID: PMC12060551.

54. Colombe M, Jeyachandran K, Mounier-Jack S, et al. (2019). HPV vaccination in Cameroon: first experience and lessons learned. *Pan Afr Med J*, 34:78.

55. District de Santé d'Edéa. (2024). *Rapport annuel d'activités du Programme Élargi de Vaccination 2023*. Edéa: Ministère de la Santé Publique.

56. Kutz JM, Rausche P, Gheit T, Puradiredja DI, Fusco D. Barriers and facilitators of HPV vaccination in sub-saharan Africa: a systematic review. BMC Public Health. 2023 May 26;23(1):974. doi: 10.1186/s12889-023-15842-1. PMID: 37237329; PMCID: PMC10214362.

57. World Health Organization (WHO). (2015). *WHO guidance on the storage and transport of temperature-sensitive pharmaceutical products*. Geneva: WHO.

58. Kaufman J, Tuckerman J, Bonner C, et al. (2021). Parent-level barriers and facilitators to HPV vaccine uptake in low- and middle-income countries: a systematic review. *Vaccine*, 39(45):6571-6582.

59. Sow C, Sanou C, Medah C, Schlumberger M, Mireux F, Ouédraogo I, Ouédraogo SM,

Betsem E. Challenges of cold chain quality for routine EPI in south-west Burkina-Faso: An assessment using automated temperature recording devices. Vaccine. 2018 Jun 18;36(26):3747-3755. doi: 10.1016/j.vaccine.2018.05.062. Epub 2018 May 18. PMID: 29779921.

60. LaMontagne, D Scott, Barge, Sandhya, Le, Nga Thi, Mugisha, Emmanuel, Penny, Mary E et al. (2011). Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bulletin of the World Health Organization, 89(11), 821 - 830B. World Health Organization. https://doi.org/10.2471/BLT.11.089862

61. LaMontagne DS, Bloem PJN, Brotherton JML, Gallagher KE, Badiane O, Ndiaye C. Progress in HPV vaccination in low- and lower-middle-income countries. Int J Gynaecol Obstet. 2017 Jul;138 Suppl 1:7-14. doi: 10.1002/ijgo.12186. PMID: 28691329.

62. Tsu VD, LaMontagne DS, Atuhebwe P, Bloem PN, Ndiaye C. National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects. Prev Med. 2021 Mar;144:106335.

doi: 10.1016/j.ypmed.2020.106335. Epub 2021 Mar 4. PMID: 33678232; PMCID: PMC7957340.

63. Layouni S. La logistique du dernier kilomètre adaptée aux produits de santé. Actualités Pharmaceutiques. 2022 Oct 1;61:26–7. doi:10.1016/j.actpha.2022.07.039

64. Périères L, Séror V, Boyer S, Sokhna C, Peretti-Watel P. Reasons given for non-vaccination and under-vaccination of children and adolescents in sub-Saharan Africa: A systematic review. Hum Vaccin Immunother. 2022 Nov 30;18(5):2076524. doi: 10.1080/21645515.2022.2076524. Epub 2022 Jun 16. PMID: 35709342; PMCID: PMC9481092.

65. Naavaal S, Boyle J, Brickhouse T, Chukmaitov A, Oliver J, Fuemmeler BF. Bridging the gap: tackling general and HPV vaccine hesitancy in rural and low-vaccination areas to improve HPV vaccine uptake. Front Public Health. 2026 Jan 27;13:1702968. doi: 10.3389/fpubh.2025.1702968. PMID: 41675078; PMCID: PMC12888034.

66. Cunningham MS, Davison C, Aronson KJ. HPV vaccine acceptability in Africa: a systematic

review. Prev Med. 2014 Dec;69:274-9. doi: 10.1016/j.ypmed.2014.08.035. Epub 2014 Oct 24. PMID: 25451327.

67. Perlman S, Wamai RG, Bain PA, Welty T, Welty E, Ogembo JG (2014) Knowledge and Awareness of HPV Vaccine and Acceptability to Vaccinate in Sub-Saharan Africa: A Systematic Review. PLoS ONE 9(3): e90912. https://doi.org/10.1371/journal.pone.0090912

68. Henschke N, Bergman H, Buckley BS, Crosbie EJ, Dwan K, Golder SP, et al. Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination - Henschke, N - 2025 | Cochrane Library [Internet]. [cited 2026 May 26]. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015363.pub2/full

69. Institut National Du Cancer. Arguments clés sur la vaccination contre les cancers HPV [Internet]. 2026 [cited 2026 May 26]. Available from: https://www.cancer.fr/professionnels-de-sante/prevention-et-depistages/prevention/agents-infectieux/prevenir-les-cancers-lies-aux-

hpv/arguments-cles-sur-la-vaccination-contre-les-cancers-hpv

70. Delawarehealth. HPV VACCINE FACTS. Available from: https://www.delawarehealth.org/wp-content/uploads/2018/01/HPV-Vaccine-Facts.pdf

71. Matsumura N, Shiro R, Tsunoda I. Critical evaluation on roles of macrophagic myofasciitis and aluminum adjuvants in HPV vaccine-induced adverse events. Cancer Sci. 2023 Apr;114(4):1218-1228. doi: https://doi.org/10.1111/cas.15714 .

72. PROTEGE QV. La désinformation : une entrave aux libertés des femmes au Cameroun ? Available from: https://www.apc.org/sites/default/files/final-documenter-les-cas-de-desinformation-au-cameroun.pdf

73. Infovac - Centre de Vaccinologie CMU. HPV: la maladie et le vaccin [Internet]. 2026 [cited 2026 May 26]. Available from: https://www.infovac.ch/fr/les-vaccins/par-maladie/hpv

74. Egawa-Takata T, Nakae R, Shindo M, Miyoshi A, Takiuchi T, Miyatake T, Kimura T. Fathers'

participation in the HPV vaccination decision-making process doesn't increase parents' intention to make daughters get the vaccine. Hum Vaccin Immunother. 2020 Jul 2;16(7):1653-1658. doi: 10.1080/21645515.2019.1697107. Epub 2020 Jan 9. PMID: 31916906; PMCID: PMC7482760.

75. UNICEF. The State of the World's Children 2023 [Internet]. 2023 [cited 2026 May 26]. Available from: https://www.unicef.org/reports/state-worlds-children-2023

76. Kabakama S, Gallagher KE, Howard N, Mounier-Jack S, Burchett HE, Griffiths UK, Feletto M, LaMontagne DS, Watson-Jones D. Social mobilisation, consent and acceptability: a review of human papillomavirus vaccination procedures in low and middle-income countries. BMC Public Health. 2016 Aug 19;16(1):834. doi: 10.1186/s12889-016-3517-8. PMID: 27543037; PMCID: PMC4992325.

77. Adamu AA, Jalo RI, Ndwandwe D, Wiysonge CS. Exploring the complexity of the implementation determinants of human papillomavirus vaccination in Africa through

a systems thinking lens: A rapid review. Hum Vaccin Immunother. 20(1):2381922. doi:10.1080/21645515.2024.2381922 PubMed PMID: 39113230; PubMed Central PMCID: PMC11312990.

78. Mouvement Mondial pour les Forêts Tropicales. Les plantations industrielles de palmiers à huile, un mode d'exploitation qui porte atteinte aux populations forestières et à leurs territoires [Internet]. 2015 [cited 2026 May 26]. Available from: https://www.wrm.org.uy/fr/articles-du-bulletin/les-plantations-industrielles-de-palmiers-a-huile-un-mode-dexploitation-qui-porte-atteinte-aux

79. Organisation Mondiale de la Santé. L'OMS ajoute un vaccin anti-HPV à administrer en dose unique [Internet]. 2024 [cited 2026 May 26]. Available from: https://www.who.int/fr/news/item/04-10-2024-who-adds-an-hpv-vaccine-for-single-dose-use

80. Njoh AA, Bolio A, Venczel L, Libwea JN, Waheed DE, Kongnyuy EJ, Amani A, Saidu Y, Dinga JN, Ngenge BM, Mbanga C, Madaina I, Abizou MB, Cleenewerck de Kiev L. Key players and determinants improving human

papillomavirus vaccination coverage in Cameroon: a cross-sectional nationwide health workers survey. Vaccine. 2026 Jan 1;69:128006. doi: 10.1016/j.vaccine.2025.128006. Epub 2025 Nov 22. PMID: 41275653.

81. Sayinzoga F, Umulisa MC, Sibomana H, Tenet V, Baussano I, Clifford GM. Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort. Vaccine. 2020 May 19;38(24):4001-4005. doi: 10.1016/j.vaccine.2020.04.021. Epub 2020 Apr 24. PMID: 32336599; PMCID: PMC7221340.

82. Mavundza EJ, Jaca A, Cooper S, Ndwandwe DE, Wiysonge CS. Factors associated with HPV vaccine acceptance and hesitancy in Africa: a systematic review protocol. BMJ Open. 2024 Nov 14;14(11):e082592. doi: 10.1136/bmjopen-2023-082592. PMID: 39542479; PMCID: PMC11575253.

83. Kabore A, Nouktara WR, Yameogo RA, Soubyabiga RJR, Nana F, Diallo AH, et al. Facteurs associés aux occasions manquées de vaccination chez les enfants de 0 à 23 mois dans les districts sanitaires de Ziniaré et Nongr-Massom au Burkina Faso en 2024.

The Pan African Medical Journal. 2025 Oct 17;51(31). doi:10.11604/pamj.supp.2025.51.1.48108

84. MediQuality. Vacciner dans les pharmacies contre le HPV? [Internet]. [cited 2026 May 27]. Available from: https://www.mediquality.net/lu/topic/article/24442438/vacciner-dans-les-pharmacies-contre-le-hpv

85. Mohamed YB and Karimi SM (2026) A comprehensive review of HPV vaccination policies in the United States.*Front. Public Health* 14:1810845. doi: 10.3389/fpubh.2026.1810845

86. Miyoshi A, Takiuchi T, Kimura T. HPV vaccination in Japan: can educational intervention promote a father's intention to encourage his daughter's vaccination? Int J Clin Oncol. 2020 Apr;25(4):746-754. doi: 10.1007/s10147-019-01575-y. Epub 2019 Nov 12. PMID: 31720985.

87. Schwarze-Chintapatla A, Livingstone-Banks J, Chua J, Albury C. Is behaviour change communication guidance for general practice healthcare professionals evidence based? A systematic review. BMC Med. 2026

Feb 16;24(1):111. doi: 10.1186/s12916-026-04681-7. PMID: 41692725; PMCID: PMC12922351.

88. Marcel EAM. Evaluation de l'efficacité des programmes de vaccination dans les zones rurales : méthodes et défis. Journal de recherche multidisciplinaire [Internet]. 2025 May 20 [cited 2026 May 27];1. Available from: https://jorep.net/index.php/revue/article/view/79

89. Pilcher F, Carney JK, Stein GS. Overcoming barriers to HPV vaccination in rural Vermont through a multicomponent peer-based approach. Hum Vaccin Immunother. 2022 Nov 30;18(6):2122494. doi: 10.1080/21645515.2022.2122494. Epub 2022 Sep 21. PMID: 36130214; PMCID: PMC9746368.